BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30885693)

  • 1. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
    Julg B; Dee L; Ananworanich J; Barouch DH; Bar K; Caskey M; Colby DJ; Dawson L; Dong KL; Dubé K; Eron J; Frater J; Gandhi RT; Geleziunas R; Goulder P; Hanna GJ; Jefferys R; Johnston R; Kuritzkes D; Li JZ; Likhitwonnawut U; van Lunzen J; Martinez-Picado J; Miller V; Montaner LJ; Nixon DF; Palm D; Pantaleo G; Peay H; Persaud D; Salzwedel J; Salzwedel K; Schacker T; Sheikh V; Søgaard OS; Spudich S; Stephenson K; Sugarman J; Taylor J; Tebas P; Tiemessen CT; Tressler R; Weiss CD; Zheng L; Robb ML; Michael NL; Mellors JW; Deeks SG; Walker BD
    Lancet HIV; 2019 Apr; 6(4):e259-e268. PubMed ID: 30885693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.
    Zheng L; Tierney C; Bosch RJ
    Curr HIV/AIDS Rep; 2021 Oct; 18(5):475-482. PubMed ID: 34213731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
    Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
    Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
    Clarridge KE; Blazkova J; Einkauf K; Petrone M; Refsland EW; Justement JS; Shi V; Huiting ED; Seamon CA; Lee GQ; Yu XG; Moir S; Sneller MC; Lichterfeld M; Chun TW
    PLoS Pathog; 2018 Jan; 14(1):e1006792. PubMed ID: 29324842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
    Lau JSY; Cromer D; Pinkevych M; Lewin SR; Rasmussen TA; McMahon JH; Davenport MP
    J Infect Dis; 2022 Aug; 226(2):236-245. PubMed ID: 35104873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.
    Papasavvas E; Lada SM; Joseph J; Yin X; Liu Q; Azzoni L; Mounzer K; Kostman JR; Richman D; Montaner LJ
    AIDS; 2018 Aug; 32(13):1763-1772. PubMed ID: 30045057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption.
    Alexandre M; Prague M; Lhomme E; Lelièvre JD; Wittkop L; Richert L; Lévy Y; Thiébaut R
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38819800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients.
    Montserrat M; Plana M; Guardo AC; Andrés C; Climent N; Gallart T; Leal L; Gatell JM; Sánchez-Palomino S; García F
    AIDS; 2017 Aug; 31(13):1895-1897. PubMed ID: 28590333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity.
    McGuinty M; Angel JB; Cooper CL; Cowan J; MacPherson PA; Kumar A; Murthy S; Sy R; Dennehy M; Tremblay N; Byrareddy SN; Cameron DW
    BMJ Open; 2020 Oct; 10(10):e041359. PubMed ID: 33033101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
    Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
    HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.
    Pai NP; Tulsky JP; Lawrence J; Colford JM; Reingold AL
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005482. PubMed ID: 16235406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.
    Sneller MC; Huiting ED; Clarridge KE; Seamon C; Blazkova J; Justement JS; Shi V; Whitehead EJ; Schneck RF; Proschan M; Moir S; Fauci AS; Chun TW
    J Infect Dis; 2020 Oct; 222(10):1655-1659. PubMed ID: 32443148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
    Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.
    Palich R; Ghosn J; Chaillon A; Boilet V; Nere ML; Chaix ML; Delobel P; Molina JM; Lucht F; Bouchaud O; Rieux V; Thiebaut R; Levy Y; Delaugerre C; Lelievre JD;
    AIDS; 2019 Feb; 33(2):279-284. PubMed ID: 30325777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
    Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
    J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
    Hellmuth J; Muccini C; Colby DJ; Kroon E; de Souza M; Crowell TA; Chan P; Sacdalan C; Intasan J; Benjapornpong K; Tipsuk S; Puttamaswin S; Chomchey N; Valcour V; Sarnecki M; Tomaka F; Krebs SJ; Slike BM; Jagodzinski LL; Dumrongpisutikul N; Sailasuta N; Samboju V; Michael NL; Robb ML; Vasan S; Ananworanich J; Phanuphak P; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2021 Oct; 73(7):e1885-e1892. PubMed ID: 32916708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
    Pai NP; Lawrence J; Reingold AL; Tulsky JP
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.
    Prator CA; Thanh C; Kumar S; Pan T; Peluso MJ; Bosch R; Jones N; Milush JM; Bakkour S; Stone M; Busch MP; Deeks SG; Hunt PW; Henrich TJ
    J Infect Dis; 2020 Mar; 221(7):1146-1155. PubMed ID: 31677350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions.
    Dubé K; Agarwal H; Carter WB; Dee L; Taylor J; Roebuck C; Peterson B; Patel H; Ndukwe S; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Bateman K; Howell BJ; Azzoni L; Mounzer K; Tebas P; Montaner LJ
    HIV Res Clin Pract; 2022 Aug; 23(1):76-90. PubMed ID: 35968737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.